Home Blog Page 2390

Huawei Cloud: Empowering Customers to Succeed in Global Markets Through Continuous Innovation

By
Advertorial Desk
-

SHANGHAI, Sept. 19, 2025 /PRNewswire/ — At HUAWEI CONNECT 2025, Charles Yang, Senior Vice President of Huawei and President of Huawei Cloud Global Marketing and Sales Service, delivered a keynote speech. He shared Huawei Cloud’s innovative technologies and practices, and shed light on how these are helping global customers achieve business success through digital and intelligent transformation. He said that Huawei Cloud will continue to innovate in technologies and build a comprehensive support system featuring “one global cloud infrastructure and two engines –data and AI”, to empower global customers and partners to achieve growth.

Charles Yang, Senior Vice President of Huawei and President of Huawei Cloud Global Marketing and Sales Service
Charles Yang, Senior Vice President of Huawei and President of Huawei Cloud Global Marketing and Sales Service

In the digital intelligence era, enterprises face complex challenges. Charles Yang introduced Huawei Cloud’s four core capabilities that can help enterprises grow. The first is KooVerse, a global cloud infrastructure that offers customers elastic cloud services. Second are data enablement services, which efficiently supply data and unleash data value. Third is a one-stop AI development platform that helps enterprises build AI-native applications with greater ease. Finally, Huawei Cloud brings together the best practices in global intelligent transformation, and provides them through cloud services.

KooVerse: Accelerating global business growth

To meet enterprises’ requirements as they expand into global markets, Huawei Cloud offers KooVerse, a global cloud infrastructure, providing enterprises worldwide with access to Huawei Cloud’s closest resources. This means enterprises can enjoy elastic, secure, and stable services, all while accelerating their global business growth.

DeFacto, a top fast fashion retailer in Türkiye, provides e-commerce services in over 100 countries and faces the challenge of traffic surging more than 10-fold during promotional seasons. Huawei Cloud’s container service, capable of the automatic capacity expansion of 4,000 pods within 30 seconds, has successfully tackled this issue. Furthermore, thanks to the Huawei Cloud KooVerse, DeFacto enjoys a response latency of less than 25 ms locally and 50 ms in Egypt, significantly boosting user satisfaction and order conversion. Since 2023, DeFacto’s services have been running stably on Huawei Cloud for 659 days, a testament to Huawei Cloud’s commitment to security, stability, and quality.

Data enablement: Rapid data insights drive better-informed decisions

Huawei Cloud provides data enablement services that help enterprises mine data value and transform their data-delay weaknesses into early-decision-making advantages. The resulting data insights help enterprises increase sales and profitability.

Neogrid, a top data intelligence and technology company in Brazil, processes massive amounts of data collected from 2 million active products and 500,000 real-time transactions carried out on POS machines daily. Previously, such data was scattered across different platforms, delaying decision making. Neogrid now uses Huawei Cloud DWS to seamlessly integrate data from across multiple platforms, enhancing data integration efficiency by 40% and analysis efficiency by 50%. This gives Neogrid’s customers the ability to obtain the day’s data before the end of work and therefore make decisions earlier.

One-stop AI application development platform: Accelerating AI-native applications

Huawei Cloud has been diving deep into industries’ core scenarios to better understand customer requirements. Huawei Cloud provides one-stop AI solutions for enterprises through full-stack innovation that encompasses compute, foundation models, and toolchains, helping enterprises build their own models and industry-specific AI applications.

Wanhua Chemical, a global leader in the chemical industry, maintains over 30,000 operating devices on its Yantai campus in Shandong, China. Traditionally, these devices incurred huge maintenance costs each year. However, by employing Huawei Cloud’s Pangu Prediction Model, Wanhua Chemical has been able to perform predictive maintenance on over 2,000 key devices, with prediction accuracy exceeding 90%. The company has also used the Pangu Inference Model to build a fault diagnosis system and achieve a 20% reduction in manual inspection time. Furthermore, Wanhua Chemical has built a standard operating procedure (SOP) document review agent on Huawei Cloud’s Versatile agent development platform, and this agent improves review efficiency by more than 50%. Huawei Cloud’s AI capabilities have been implemented in more than 500 scenarios across over 30 industries, enabling enterprises to leap forward in intelligent transformation.

Co-creating transformation best practices: Enabling enterprises’ high-quality global development

Huawei Cloud transforms its experience in digital and intelligent transformation into a replicable reference architecture for the intelligent transition of industries, and provides this to customers through cloud services, enabling high-quality enterprise development.

Changan Automobile has utilized Huawei Cloud’s CodeArts to transform its R&D from a waterfall-style methodology to one that is based on a unified platform, thus boosting R&D efficiency by 30%. Huawei has also supported Changan Automobile by working alongside partners like China Unicom to build “One Cloud, One Network, One Platform”, driving flexible manufacturing with data. Within this platform, 5G and IoT are used to connect 12,000 devices, helping Changan Automobile interconnect data from across every domain. Furthermore, based on Huawei Cloud’s comprehensive data service capabilities, Changan Automobile has constructed a unified data platform, reducing delivery lead time for orders from 21 days to just 15.

Charles Yang highlighted Huawei Cloud’s systematic, end-to-end capabilities that span the cloud foundation, technology enablement toolchains, and experiences, as well as its tailored consulting and professional services, and automation tools and platforms. These offerings are rapidly accelerating the digital and intelligent transformation of enterprises. Huawei Cloud is ready to offer its technology, experiences, and services to enterprises worldwide, work alongside them to build a solid cloud foundation that empowers every step of their transformation, and start a historic journey towards the intelligent era.

Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

By
Advertorial Desk
-

SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it will release the latest preclinical data of ATG-201 (CD19 x CD3 TCE) in Poster Presentations at the 2025 American College of Rheumatology (ACR) Annual Meeting, taking place from October 24th to October 29th in Chicago, IL, the United States.

AnTenGagerTM is Antengene’s proprietary TCE 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. ATG-201 is a novel “2+1” CD19-targeted T-cell engager developed on the AnTenGagerTM TCE platform for the treatment of autoimmune diseases. ATG-201 is poised to enter clinical development in Q4 2025.

Details of the Poster Presentations:
ATG-201（CD19 x CD3 TCE）
Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Abstract Number: 0001
Session: (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I
Date: Sunday, October 26
Time: 10:30 AM – 12:30 PM (Central Time)
           00:30 AM – 02:30 AM, October 27 (Beijing Time)

About Antengene

Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com 
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000

 

European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

By
Advertorial Desk
-

SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.[1],[2]

“The EC approvals of BILDYOS and BILPREVDA mark a pivotal moment in expanding access to essential bone care treatments for millions of Europeans, particularly women, who are disproportionately affected by osteoporosis,” said Nico Van Hoecke, Head, International Commercial at Organon.[3],[4] “These biosimilars may offer additional treatment options across several therapeutic areas associated with bone loss, including osteoporosis, and reflect Organon’s commitment to advancing women’s health through access to important medicines.[4] These approvals, following those in the United States, not only expand the global reach of these biosimilars but also support the sustainability of Europe’s health care systems.”[5],[6]

“These approvals are a testament to the strong collaboration between Henlius and Organon aimed at meeting the needs of both patients and the health care system in Europe,” said Ping Cao, Chief Business Development Officer and Senior Vice President of Henlius. “Through our commitment to scientific excellence and product quality, we’re building on approvals in the United States to bring these biosimilar treatment options to people who need them around the world.”[6]

BILDYOS is indicated for treatment of osteoporosis in postmenopausal women and in men at increased risk for fracture, treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. BILPREVDA is indicated for the prevention of skeletal related events in adults with advanced malignancies involving bone, and treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

BILDYOS and BILPREVDA were approved based on the review of a comprehensive data package, which included structural and functional analytical data, clinical pharmacokinetic data, and a comparative clinical study demonstrating that BILDYOS and BILPREVDA are each a biological medicine highly similar to another biological medicine already approved in the EU (called ‘reference medicine’) in terms of structure, biological activity and efficacy, safety and immunogenicity profile (the intrinsic ability of proteins and other biological medicines to cause an immune response).[4]

In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to several biosimilars, including BILDYOS and BILPREVDA. The agreement covers exclusive global commercialization rights except for China.[7]

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. To date, 9 products have been approved for marketing across multiple countries and regions, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANSIZHUANG (serplulimab, trade name: Hetronifly in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANLIKANG (rituximab), the first China-developed biosimilar, and denosumab BILDYOS and BILPREVDA. What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

About Organon

Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about expectations regarding the business opportunities and prospects for BILDYOS and BILPREVDA. Forward-looking statements may be identified by words such as “will,” “potential,” “aim,” “explore,” “opportunity,” “expect,” “future,” “working to,” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, an inability to market BILDYOS and BILPREVDA; factors that could adversely affect the level of demand for BILDYOS and BILPREVDA (including trade protection measures and import or export licensing requirements; changes in US and foreign federal, state, and local governmental funding allocations, including the timing and amounts allocated to Organon’s customers and business partners; and economic factors); the failure of any supplier to provide substances, materials, or services as agreed; the increased cost of supply, manufacturing, packaging, and operations; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid, and health care reform, pharmaceutical reimbursement, and pricing in general; manufacturing difficulties or delays; restructurings or other disruptions at the FDA and other government agencies; efficacy, safety, or other quality concerns; and future actions of third-parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits, and forgoing health care insurance coverage. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the SEC, including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings (including Organon’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025), available at the SEC’s Internet site (www.sec.gov). References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Organon is not responsible for the contents of third-party websites.

PROLIA and XGEVA are trademarks registered in Europe by Amgen, Inc.; Organon is not associated with this trademark owner.

[1] PROLIA. Product Information. Amgen; 2025.

[2] XGEVA. Product Information. Amgen; 2025.

[3] J. Kanis, Norton, N., Harvey, N., et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Archives of Osteoporosis. (2021) 16:82. Accessed September 15, 2025. Available at https://www.osteoporosis.foundation/sites/iofbonehealth/files/202106/Kanis2021_Article_SCOPE2021ANewScorecardForOsteo.pdf 

[4] Biosimilar medicines: overview. European Medicines Agency (EMA). April 2, 2025. Accessed September 15, 2025.

https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview.

[5] Troein P, Max Newton, Stoddart K, Travaglio M, Aurelio Arias. The impact of biosimilar competition in Europe. 2025. Accessed

September 15, 2025.

https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2024.pdf.  

[6] US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively. Organon. Published September 2, 2025. Accessed September 15, 2025. https://www.organon.com/news/us-food-and-drug-administration-fda-approves-henlius-and-organons-bildyos-denosumab-nxxp-and-bilprevda-denosumab-nxxp-biosimilars-to-prolia-denosumab-and-xgeva-denosumab/ 

[7] Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta ®(Pertuzumab) and Prolia ®/Xgeva ®(Denosumab) Biosimilar Candidates. Organon. June 13, 2022. Accessed September 15, 2025. https://www.organon.com/news/organon-enters-into-global-license-agreement-to-commercialize-henlius-investigational-perjeta-pertuzumab-and-prolia-xgeva-denosumab-biosimilar-candidates/

Su Dongpo Witnesses Electricity Lighting the Path to Common Prosperity

By
Advertorial Desk
-

HANGZHOU, CHINA – Media OutReach Newswire – 19 September 2025 – As the Autumn Equinox approaches, people prepares to celebrate the 8th Farmers’ Harvest Festival. Su Dongpo, the famed poet of the Northern Song dynasty, “traveled” across a thousand years find himself at the tea garden of Jingshan in Hangzhou. There, he encounters farmer Lu Xiaoyu hosting a livestream——a vivid snapshot of Zhejiang’s journey toward common prosperity.

Su Dongpo encounters farmer Lu Xiaoyu hosting a livestream——a vivid snapshot of Zhejiang’s journey toward common prosperity.
Su Dongpo encounters farmer Lu Xiaoyu hosting a livestream——a vivid snapshot of Zhejiang’s journey toward common prosperity.

Tea leaves in the electric roasting machine releases a rich, mellow aroma. Smiling at the camera, Lu Xiaoyu counts down:”3, 2, 1, link’s up!” Right on cue, electric power workers plug in the equipment. The lights brighten the tea table, fans sweep away the heat, and the fragrance of fresh tea flows the current into orders across the nation.

image-1.jpeg

Solar panels in the tea garden “borrow” sunlight to generate power, while the Xin’an river hydropower station gather the force of water and light . Electricity is breathing new life into the countryside. From the curling smoke over Yanzhou Ancient Town, to the glowing lamps along Dongpo Road, to the dazzling night view of West Lake——every scene bears the imprint of electricity driving common prosperity.

The moonlight on the Autumn Equinox remains unchanged since ancient times, but the villages have been reborn. Where Su Dongpo meets modern electric power, a new chapter is being written——one of urban-rural integration, quietly fueling Zhejiang’s path toward common prosperity.

Hashtag: #SuDongPo

The issuer is solely responsible for the content of this announcement.

$ASTER TGE Day-One Performance Shines: Exclusive Aster DEX Launch Drives $371 Million Trading Volume and nearly 330,000 New Users

By
Advertorial Desk
-

MAHE, Seychelles, Sept. 19, 2025 /PRNewswire/ — The native token of decentralized exchange Aster, $ASTER, made a strong market debut with first-day metrics highlighting both investor demand and deep liquidity formation. Within the first 24 hours of its Token Generation Event (TGE), the token’s exclusive spot listing on Aster DEX established the platform as the sole global venue for $ASTER trading, attracting significant capital inflows and trading activity.

Exclusive Aster DEX Launch Drives $371 Million Trading Volume and nearly 330,000 New Users
Exclusive Aster DEX Launch Drives $371 Million Trading Volume and nearly 330,000 New Users

According to on-chain data, $ASTER recorded $371 million in trading volume on its first day. After opening at $0.03015, it climbed to a daily high of $0.528, an increase of roughly 1,650%. This highlighted strong market confidence and laid the foundation for sustained liquidity growth.

The scarcity-driven launch also accelerated adoption. Within 24 hours, nearly 330,000 new wallet addresses joined the network. Over the same period, total value locked (TVL) rose by $660 million to reach $1.005 billion, while total trading volume across the platform approached $1.5 billion, signaling consistent net inflows.

Industry analysts note that these early results strengthen Aster DEX’s position as a next-generation flagship on BNB Chain. With momentum building and participation rising, $ASTER is seen as a catalyst for the next wave of growth in decentralized finance, injecting fresh energy into the BNB Chain ecosystem. Building on this early momentum, $ASTER was scheduled to go live on Binance Alpha at 08:00 UTC on September 19.

Hisense Unveils ‘Boundless’ Vision at 2025 Laser Display Conference

By
Advertorial Desk
-

QINGDAO, China, Sept. 19, 2025 /PRNewswire/ — Hisense, a leading brand in global consumer electronics and home appliances, hosted the 2025 Laser Display Technology and Industry Development Conference under the theme “Boundless,” celebrating a decade of innovation and reaffirming its vision to break display limits.


“Boundless” reflects the spirit of Laser display—scaling from 65 to 300 inches, from homes to cars, from cinemas to industrial application scenarios—and its rise over the past decade from an emerging concept to the center of the global TV industry, evolving from niche exploration to a shared global ecosystem.

According to Technavio’s 2025 report, the global projector market has shown continuous growth, with the market expanding for three consecutive years from 2020 to 2023. This market performance further validates Hisense’s leading position. According to Omdia’s latest H1 2025 report, Hisense has maintained the No.1 position in global laser TV shipments every year from 2019 through the first half of 2025, holding a 70.0% volume share in H1 2025. From January to August 2025, Hisense Laser products also achieved 85% sales growth and 64% revenue growth in overseas markets excluding China and Japan, underscoring its global leadership.

At the conference, Hisense showcased its global lineup embodying “Boundless.” The L9Q TriChroma Laser TV and C2 Ultra triple color Laser Mini Projector, already available overseas, bring cinema-grade immersion and large-scale entertainment into homes. The L9Q Laser TV, developed with the Opéra de Paris and Devialet, delivers premium viewing from 80 to 200 inches with 5,000 ANSI Lumens, 5,000:1 contrast, with certifications including IMAX Enhanced and Dolby Vision, elevating home theater to the next level. The C2 Ultra, designed for Xbox, projects up to 300 inches with ultra-low latency and vivid color for gamers and movie fans.

Hisense also unveiled the world’s first integrated Rollable Laser TV, a compact innovation combining screen and engine, eliminating cabinets and pre-installation surveys while blending seamlessly into interiors, truly elevating beauty from inside out.

By advancing the boundaries of size, color, form, and viewing experience, Hisense reinforces its role as a global technology leader and lifestyle creator, driving the industry forward and opening a new “Boundless” era of display.

About Hisense

Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 1 globally in the 100-inch and over TV segment (2023- H12025). As the official sponsor of the FIFA World Cup 2026™, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.

Nikon Enters Cinema Space with Nikon ZR, Brings Cinematic Precision to a Compact, All-in-One Body

By
Advertorial Desk
-

Equipped with internal 6K RAW, cinematic colour workflows, and the world’s first*[1] 32-bit float recording, the Nikon ZR sets a new bar for compact cinema cameras

SINGAPORE, Sept. 19, 2025 /PRNewswire/ — Nikon Singapore Pte. Ltd. has officially launched the ZR, a full-frame sensor camera and the smallest model in the Z CINEMA series. Developed in collaboration with RED, a subsidiary of Nikon Corporation, RED Digital Cinema, Inc. (hereinafter “RED”), the ZR delivers high-end cinematic videos through its internal 6K RAW recording, RED-curated colour science, and pro-level audio—all in a lightweight body in a single body kit.

Compact Size, No Compromises

Weighing just 540g*[2], the ZR is one of the lightest cinema cameras in its class. Engineered for on-the-go filmmaking, its dust-and-drip resistant magnesium alloy body delivers reliability in any setting, from the studio to the great outdoors.

Despite its small set-up, ZR is designed to replace bulky multi-component rigs with the following features:

  • Internal 6K RAW video capture (R3D NE*[3], N-RAW, ProRes RAW HQ)
  • In-camera 32-bit float with 3.5mm jack audio recording with OZO Audio*[4] support
  • Dual Base ISO for optimised exposure control
  • Direct cloud uploads via Frame.io through NX MobileAir*[5]
  • Efficient heat dissipation, allowing 2h+ of silent, continuous recording without overheating

Built-in Cinematic Output

Designed to give filmmakers complete creative control right out of the box— Nikon ZR combines cinematic presets, colour flexibility, and advanced monitoring tools in one streamlined system. Its dedicated Cinematic Video Mode applies standardised shutter angle, frame rate, and colour tone settings for consistent, high-quality output. For stylised looks, users can select from nine RED-curated Imaging Recipes*[6], which can be previewed in real time for immediate application.

Notwithstanding, the ZR can support recording in seven video formats, including 12-bit RAW for maximum tonal range and post-production flexibility, 6K/59.94p and 4K/119.88*[7]p 12-bit RAW recording in REDWideGamutRGB and Log3G10 profiles, marking the first integration of the RED R3D NE codec into a Nikon camera.

The ZR supports LUT monitoring to its 4.0-inch LCD, allowing easy colour grading previews. The ZR also includes real-time waveform, histogram, and multi-colour zebra overlays, and with support for up to ten 65-point*[8] LUTs, alongside 17 and 33-point LUTs for accurate preview or baked-in colour. A configurable shutter angle range of 5.6° to 360° allows for true cinematic motion blur, while its deep-learning autofocus system with 273 AF points, 90% x 90% coverage, across nine categories—including people, animals, vehicles, and aircraft. Face detection is capable of recognising subjects as small as 3% of the frame, providing reliable focus even in wide compositions or fast-moving scenes.

Built for Live, Remote, and Multi-Cam Workflows

Engineered for modern productions, the ZR offers the connectivity, audio performance, and system versatility demanded by today’s filmmakers—all in a complete, self-contained body.

Featuring a comprehensive HDMI and USB-C connectivity, HDMI-CEC*[9] tally light compatibility, and ON AIR / PREVIEW indicators, making it an ideal choice for studio-based workflows, multi-camera environments, and even livestreaming.

The ZR’s efficiency in dissipate heat enables silent operation during takes and supports extended recording without the risk of noise interference or mechanical failure, while its Z mount system ensures flexibility with a wide range of native lenses, while also supporting adapted third-party options*[10] for specialised needs.

On the audio front, the ZR includes the world’s first native 32-bit float with 3.5mm jack recording, capturing a wide dynamic range without the risk of clipping, even with just the internal microphone. Its integrated OZO Audio system offers five pickup patterns*[11]—including voice-isolated and 360° modes—and pairs seamlessly with the optional ME-D10 shotgun microphone for broadcast-quality capture without batteries or XLR inputs.

Wireless, Non-Battery-Operated ME-D10 Shotgun Microphone Brings Exceptional Convenience

The ME-D10 is a 32-bit float shotgun microphone compatible with the new digital accessory shoe developed for the ZR. It requires no battery or cable, and the adoption of a shock mount and its compact design make for easy handling.

The microphone offers two recording modes, PURE and FOCUS, which can be selected with a switch on the microphone. PURE features a wide dynamic range and a sound design true to the original source, allowing natural and accurate capture of raw audio, including the ambient atmosphere while FOCUS accurately captures the intended voice, even in noisy surroundings such as those outdoors, ensuring clear audio for product presentations and live streams.

Key Specifications

  • RED R3D NE codec
  • Internal RAW video: 6K/60p (R3D NE, N-RAW, ProRes RAW HQ)
  • Dual base ISO: 800/6400
  • Dynamic range: 15+ stops*[12]
  • Audio: 32-bit float, OZO Audio, 3.5mm line input
  • Slow motion: Up to 10x slow motion in Full HD (FHD 239.76p) and presets for 4 x straight-out-of-camera slow motion
  • Cloud-ready: Frame.io integration
  • Monitoring: Waveform, histogram, LUTs
  • Stabilisation: 5-axis IBIS
  • Build: Magnesium alloy, dust-and-drip resistant
  • Weight: 540g

Z CINEMA launches official Instagram account

In conjunction with the launch of Nikon ZR, users can receive timely updates on new products, upcoming events, and other information of interest to filmmakers and content creators through its Z Cinema Instagram account.

URL: https://www.instagram.com/zcinema_

For more information, please visit https://nikon-asia.com.

About Nikon

Nikon is the world leader in digital imaging, precision optics and photo imaging technology and is globally recognised for setting new standards in product design and performance for its award-winning consumer and professional photographic equipment. Nikon Singapore Pte Ltd distributes consumer and professional digital SLR cameras, NIKKOR optics, Speedlights and system accessories; Nikon COOLPIX compact digital cameras; Nikon sports optics as well as the latest mirrorless cameras in over 50 countries.

For more information, visit https://nikon-asia.com, or discover the Z series mirrorless camera system and experience new possibilities here, http://nikn.ly/Zseries.

Connect with Nikon and other photographers on Facebook at www.facebook.com/NikonAsia, Instagram at www.instagram.com/NikonAsia, YouTube at www.youtube.com/NikonAsia and LinkedIn www.linkedin.com/company/nikonasia.

*[1] Among cameras with interchangeable lenses that record audio via the built-in microphone and 3.5-mm stereo mini-pin jack.

*[2] Camera body only: approx. 630 g including battery and recording media. 

*[3] A dedicated codec developed for Nikon cameras to record video in R3D format. The file extension is “.R3D”.

*[4] OZO is a registered trademark of Nokia Technologies Oy.

*[5] Software availability varies by market. For more information, please contact your local Nikon service center.

*[6] Imaging Recipes must be downloaded from Nikon Imaging Cloud beforehand.

*[7] Image area will be cropped to [DX] format (APS-C size).

*[8] With recording at video frame rates of 23.976p, 25p, 29.97p, 50p, and 59.94p.

*[9] Up to six cameras can be connected.

*[10] Certain features may be unavailable when other brands lens adapters are used.

*[11] Available when recording with H.264 or H.265 at 59.94p or lower.

*[12] Value based on measurement performed by Nikon.

 

NOARK Showcased at RE+ 2025 and NECA 2025 to Empower the Development of Renewable Energy and Electrical Industry

By
Advertorial Desk
-

NOARK Showcased Renewable Energy Breakthroughs at RE+ 2025, Las Vegas

CHICAGO, Sept. 19, 2025 /PRNewswire/ — NOARK Electric, a global leader in circuit protection, motor control, and power distribution solutions, showcased at RE+ 2025, Las Vegas.

Renewable Energy Solutions of NOARK

NOARK brought renewable energy to life with two must-see highlights:

  • 3D Life-Size Natural Ester Oil-Filled Transformer Model — View a full-scale model to understand how NOARK’s transformer technology powers critical applications.
  • Interactive “Sand Table” Demo — Explore dynamic scenarios where electrical grids are powered up by NOARK’s transformers, switchboards, and circuit protection solutions, simulating real-world renewable energy and T&D challenges.

Our solution spans AC Grid-Connected systems, Energy Storage solutions and EV Charging infrastructure with products like Circuit Protection Breakers, Switches, Contactors, LV Switchboards, HV Oil-filled power transformers, HV insulators, MV Pad Mounted Transformers, MV fuse Cut-outs and Surge Arresters.

Meeting the Challenges of Renewable Energy Industry

These products of NOARK are engineered to deliver superior safety, durability, and efficiency. NOARK’s solutions help overcome industry challenges by providing robust and adaptable technologies that support the integration of renewable sources, and ensure continuous power delivery. With a focus on proven reliability and innovation, NOARK empowers utilities and developers to build efficient, future-ready clean energy systems globally.

NOARK illustrates how these solutions work together to overcome real-world challenges in renewable integration and transmission. By delivering robust, UL-certified, and interoperable systems, NOARK helps developers, utilities, and EPC contractors reduce downtime, lower lifetime costs, and accelerate the transition to a more reliable and sustainable energy future.

“At NOARK, we believe renewable energy requires not just vision, but proven, reliable technology that keeps grids resilient and efficient,” said Patrick Woodham, General Manager, USA and Canada, NOARK Electric. “We are proud to showcase how our transformers, circuit protection, and control solutions power the future of clean energy.”

NOARK Showcased Next-Gen Technology at NECA 2025, Chicago

NOARK Electric, a global manufacturer and supplier of low, medium and high-voltage electrical solutions for OEMs, contractors, and distributors, brought its cutting-edge Ex9VF7 Variable Frequency Drives (VFDs) at NECA 2025, Chicago.


Spotlight Product: Ex9VF7 Variable Frequency Drives

Engineered for precision, performance, and energy efficiency, key benefits of NOARK’s Ex9VF7 VFDs include:

  • Innovation & Design
    Advanced DSP technology for high-tech motor control
    Compact design for seamless Panel/MCC integration
    Flexible inverter control with customizable I/O mapping
  • Performance & Reliability
    Automated carrier wave oscillation for reduced audible noise
    Automated torque profiling for high-torque, low-speed applications
    NEMA 1 enclosure (IP20 protection)
  • Certifications & Connectivity
    UL 61800-5-1 (US & Canada certified)
    BACnet, Ethernet IP, CANopen, and Modbus communication options

Available in operational voltages ranging from Single-phase 110V to Three-phase 600V, the Ex9VF7 covers power ratings from 0.4kW to 185kW (0.25HP–250HP)—making it a versatile choice for pumps, fans, conveyors, and other industrial applications.

Why NOARK VFDs Matter in Today’s Industry

NOARK’s VFDs are more than just components—they’re intelligent systems enhancing operational efficiency and sustainability. They achieve this by:

  • Optimizing Motor Operation:
    Continuously monitoring motor performance and adjusting output in real-time—notably through a control loop that ensures precise speed and power delivery.
  • Boosting Efficiency & Longevity:
    By aligning motor output to actual demand, VFDs avoid energy waste and minimize mechanical stress, thereby extending equipment life.
  • Delivering Long-Term Value:
    While VFDs may require more upfront investment and expertise, their returns in productivity, maintenance savings, and operational control far outweigh the initial costs.

Meeting the Challenges of Electrification

NOARK Electric addresses critical challenges facing the modern power industry by delivering intelligent, high-efficiency, and reliably certified solutions. Our products are engineered to enhance grid stability, reduce energy waste, and simplify integration in complex industrial and commercial environments. For instance, the Ex9VF7 VFD optimizes motor-driven systems with precision control, significantly lowering power consumption in pumps, fans, and conveyors—directly tackling energy inefficiency.

Our UL-certified Pad Mount Transformers and modular LV Switchboards offer robust, safe, and adaptable power distribution, enabling seamless expansion in data centers, renewable integration, and facility upgrades. With advanced communication capabilities and standardized certifications, NOARK ensures interoperability and future-ready performance, empowering operators and contractors to meet evolving demands for reliability, sustainability, and cost-effective electrical infrastructure.

“NOARK is committed to empowering the electrical industry with innovative, efficient, and reliable solutions—designed with electrical contractors in mind,” said Patrick Woodham, General Manager, USA and Canada, NOARK Electric. “Events like the NECA Conference give us the opportunity to connect directly with customers, demonstrate our technology, and reinforce our mission of redefining standards through innovation.”

1...2,3892,3902,391...6,491Page 2,390 of 6,491